Development of carbohydrate based anticancer agents

CarboMed will assess the commercial viability of targeting cancer cell glycosylation as a next-generation therapeutic strategy to treat cancer in the clinic. Carbohydrates (glycans) coat the cell of every organism. The glycosylation pattern of cancer cells is, however, very different from that of healthy cells and is associated with aggressive and invasive forms of cancers. By combining our knowledge on carbohydrate chemistry and cancer immunology we targeted the cancer-cell protecting carbohydrate coat, hampering the cancer's ability to grow and metastasize. In this project, we aim to deliver a technical and commercial proof-of-concept for targeting the glycosylation of cancer cells to ultimately enable clinical studies